U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2014
503
Substance Class Protein
Created
by admin
on Mon Mar 31 21:13:53 GMT 2025
Edited
by admin
on Mon Mar 31 21:13:53 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG4
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
31YO63LBSN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OPDIVO
Preferred Name English
NIVOLUMAB
DASH   INN   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
OPDUALAG COMPONENT NIVOLUMAB
Brand Name English
BMS-986213 COMPONENT NIVOLUMAB
Common Name English
MDX-1106
Code English
OPDIVO QVANTIG COMPONENT NIVOLUMAB
Brand Name English
BMS-936558
Code English
NIVOLUMAB [USAN]
Common Name English
NIVOLUMAB [JAN]
Common Name English
NIVOLUMAB [MI]
Common Name English
nivolumab [INN]
Common Name English
NIVOLUMAB [PURPLE BOOK CDER]
Common Name English
NIVOLUMAB [VANDF]
Common Name English
MDX1106
Code English
Nivolumab [WHO-DD]
Common Name English
BMS-986298
Code English
ONO-4538
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 591617
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
NDF-RT N0000191260
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
NCI_THESAURUS C129822
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
EMA ASSESSMENT REPORTS OPDIVO (AUTHORIZED: MELANOMA)
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 670918
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 595817
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
NCI_THESAURUS C128037
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
EMA ASSESSMENT REPORTS NIVOLUMAB BMS( WITHDRAWN: CARCINOMA, NON-SMALL-CELL LUNG)
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 442614
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 595017
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 469615
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 641718
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 545016
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 445014
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 387612
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 489915
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 491415
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 595917
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
WHO-ATC L01XC17
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
FDA ORPHAN DRUG 531016
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
Code System Code Type Description
MESH
C551361
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
FDA UNII
31YO63LBSN
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
INN
9623
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
MERCK INDEX
m11824
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
SMS_ID
100000145087
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
DRUG CENTRAL
4923
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
RXCUI
1597876
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY RxNorm
CAS
946414-94-4
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
EVMPD
SUB122750
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
IUPHAR
7335
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
NDF-RT
N0000191259
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY Programmed Death Receptor-1-directed Antibody Interactions [MoA]
DAILYMED
31YO63LBSN
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
DRUG BANK
DB09035
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108738
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
USAN
YY-151
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
WIKIPEDIA
Nivolumab
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
LACTMED
Nivolumab
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
NCI_THESAURUS
C68814
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
HSDB
8256
Created by admin on Mon Mar 31 21:13:54 GMT 2025 , Edited by admin on Mon Mar 31 21:13:54 GMT 2025
PRIMARY
From To
1_22 1_96
1_140 1_196
1_254 1_314
1_360 1_418
2_22 2_96
2_140 2_196
2_254 2_314
2_360 2_418
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
1_127 3_214
2_127 4_214
1_219 2_219
1_222 2_222
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_290
N 2_290
Related Record Type Details
PROGRAMMED CELL DEATH PROTEIN 1
TARGET -> INHIBITOR
Related Record Type Details
NIVOLUMAB
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION [1_1] [2_1] N-TERMINUS Amount: PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966